Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated ste… Read more
Market Cap & Net Worth: Thiogenesis Therapeutics Corp. (TTI)
Thiogenesis Therapeutics Corp. (V:TTI) has a market capitalization of $17.14 Million (CA$24.62 Million) as of March 19, 2026. Listed on the V stock exchange, this Canada-based company holds position #26988 globally and #145 in its home market, demonstrating a -5.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Thiogenesis Therapeutics Corp.'s stock price CA$0.48 by its total outstanding shares 51835956 (51.84 Million).
Thiogenesis Therapeutics Corp. Market Cap History: 2022 to 2026
Thiogenesis Therapeutics Corp.'s market capitalization history from 2022 to 2026. Data shows change from $20.93 Million to $17.14 Million (-1.30% CAGR).
Thiogenesis Therapeutics Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Thiogenesis Therapeutics Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TTI by Market Capitalization
Companies near Thiogenesis Therapeutics Corp. in the global market cap rankings as of March 19, 2026.
Key companies related to Thiogenesis Therapeutics Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Thiogenesis Therapeutics Corp. Historical Marketcap From 2022 to 2026
Between 2022 and today, Thiogenesis Therapeutics Corp.'s market cap moved from $20.93 Million to $ 17.14 Million, with a yearly change of -1.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$17.14 Million | -26.92% |
| 2025 | CA$23.46 Million | +8.33% |
| 2024 | CA$21.65 Million | -20.00% |
| 2023 | CA$27.07 Million | +29.31% |
| 2022 | CA$20.93 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Thiogenesis Therapeutics Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.14 Million USD |
| MoneyControl | $17.14 Million USD |
| MarketWatch | $17.14 Million USD |
| marketcap.company | $17.14 Million USD |
| Reuters | $17.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.